SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001493152-23-043798 from ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc.
Date: Dec. 6, 2023 · CIK: 0001859007 · Accession: 0001493152-23-043798

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-275320

Date
Dec. 6, 2023
Author
Managing Director
Form
CORRESP
Company
ZyVersa Therapeutics, Inc.

Letter

A.G.P./ALLIANCE GLOBAL PARTNERS

Madison Avenue 28th Floor New York,

New York 10022

December 6, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: ZyVersa Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-1

File No. 333-275320 (the “Registration Statement”)

Ladies and Gentlemen:

In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, (the “Act”), A.G.P./Alliance Global Partners, as the sole placement agent, hereby joins the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 5:00 p.m., Eastern Time on December 6, 2023, or as soon thereafter as practicable.

The undersigned, as the sole placement agent, represents that it has and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Please contact Katherine J. Blair of Manatt, Phelps & Phillips, LLP, counsel of the placement agent, at (310) 312-4252 to provide notice of effectiveness, or if you have any questions or concerns regarding the foregoing. We appreciate your assistance in this matter.

Very truly yours,
A.G.P./ALLIANCE GLOBAL PARTNERS

Show Raw Text
CORRESP
1
filename1.htm

A.G.P./ALLIANCE
GLOBAL PARTNERS

590
Madison Avenue 28th Floor New York,

New
York 10022

December
6, 2023

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    ZyVersa
    Therapeutics, Inc. (the “Company”)

    Registration
    Statement on Form S-1

    File
    No. 333-275320 (the “Registration Statement”)

Ladies
and Gentlemen:

In
accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, (the “Act”),
A.G.P./Alliance Global Partners, as the sole placement agent, hereby joins the Company’s request for acceleration of the above-referenced
Registration Statement, requesting effectiveness for 5:00 p.m., Eastern Time on December 6, 2023, or as soon thereafter as practicable.

The
undersigned, as the sole placement agent, represents that it has and will comply with the requirements of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended.

Please
contact Katherine J. Blair of Manatt, Phelps & Phillips, LLP, counsel of the placement agent, at (310) 312-4252 to provide notice
of effectiveness, or if you have any questions or concerns regarding the foregoing. We appreciate your assistance in this matter.

    Very truly yours,

    A.G.P./ALLIANCE GLOBAL PARTNERS

    By:
    /s/
Thomas Higgins

    Name:
    Thomas Higgins

    Title:
    Managing Director